Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.2.1.7 (BAL)
 1,977 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Current testing conventions for inhalation toxicity studies require that solid and non-volatile liquid compounds are converted to respirable aerosol, which is often achieved by laboratory-specific technical methodologies. So far, internationally harmonized approaches are lacking that would allow comparison of results from inhalation studies with 'contrived' test aerosols taking into account the actual particle size of the product as it might be encountered in normal handling and use. The focus of this paper is to consider aerosols of irritant substances eliciting their mode of action on sites of initial deposition within the respiratory tract of rats. Assessment is based on conventional endpoints, such as mortality (LC(50)), and sublethal endpoints that include an analysis for the concentration-effect relationship of protein in bronchoalveolar lavage fluid (BAL-protein) as a sensitive, early marker of lung edema. This retrospective analysis also addresses whether common denominators can be found for different aerosol sizes of direct and indirect irritants, such as monomeric and polymeric diphenylmethane-4,4'-diisocyanate (mMDI and pMDI), naphthylene diisocyanate (NDI), dicyclohexylmethane-4,4'-diisocyanate (HMDI), 2,4-triisopropyl-benzene-diisocyanate (TRIDI) and substances (e.g., chlorofluoroalkyl side-chain fungicides) known to decompose to irritant intermediates in the lining fluids of the airways. Collectively, this analysis shows that for irritant aerosols both the concentration and the particle size are equally important for the outcome of the test, independent of whether the endpoint chosen is lethality or BAL protein. The scientific value of 1-h exposures to high aerosol concentrations, as required by some regulations, could be challenged because high concentrations and high respirability of aerosol appear to be mutually exclusive, as shown for mMDI and NDI (LC(50 )>2000 mg/m(3)). Thus, for a meaningful risk characterization, test results from inhalation studies with 'contrived properties' due to the specific techniques employed need to be compared with the real properties of substances as marketed, handled and used.
 ...
PMID:Acute inhalation studies with irritant aerosols: technical issues and relevance for risk characterization. 1505 6

Procedures are described for the determination of arsenite, arsenate and monomethylarsonic acid in aqueous samples. The arsenicals (after reduction of arsenic to the tervalent state) readily react with 2,3-dimercaptopropanol (BAL) to yield their BAL complexes. The products are extracted with benzene and introduced into a gas Chromatograph equipped with a flame-photometric detector for sulphur. One aliquot of sample is treated with stannous chloride solution and potassium iodide solution to reduce arsenate and monomethylarsonic acid, then BAL is added and the complexes are extracted with benzene. The extract is analysed for total inorganic As plus monomethylarsonic acid. Magnesia mixture and phosphate solution are added to another aliquot to remove arsenate by co-precipitation with magnesium ammonium phosphate. The precipitate is filtered off and arsenite determined in the filtrate. The detection limits are 0.02 ng of As for arsenate and arsenite and 0.04 ng of As for monomethylarsonic acid.
 ...
PMID:Determination of arsenite, arsenate and monomethylarsonic acid in aqueous samples by gas chromatography of their 2,3-dimercaptopropanol (bal) complexes. 1896 24